International Journal of Radiation Oncology * Biology * Physics
Volume 70, Issue 4 , Pages 1219-1228 , 15 March 2008

The Influence of Changes in Tumor Hypoxia on Dose-Painting Treatment Plans Based on 18F-FMISO Positron Emission Tomography

  • Zhixiong Lin, M.D.

      Affiliations

    • Department of Radiation Oncology, Shantou University Medical College–Cancer Hospital, Shantou, China
    • ,
  • James Mechalakos, Ph.D.

      Affiliations

    • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
    • ,
  • Sadek Nehmeh, Ph.D.

      Affiliations

    • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
    • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
    • ,
  • Heiko Schoder, M.D.

      Affiliations

    • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
    • ,
  • Nancy Lee, M.D.

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
    • ,
  • John Humm, Ph.D.

      Affiliations

    • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
    • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
    • ,
  • C. Clifton Ling, Ph.D.

      Affiliations

    • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
    • Varian Medical Systems, Palo Alto, CA
    • Corresponding Author InformationReprint requests to: C. Clifton Ling, Ph.D., Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10021. Tel: (212) 639-8301; Fax: (212) 717-3010

Received 17 August 2007 ,Revised 20 September 2007 ,Accepted 21 September 2007.

References 

  1. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–1804
  2. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol. 2005;23:1125–1135
  3. Chao KSC, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: Initial results. Int J Radiat Oncol Biol Phys. 2001;49:907–916
  4. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12–22
  5. Lee N, Xia P, Fischbein NJ, et al. Intensity-modulated radiation therapy for head-and-neck cancer: The UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys. 2003;57:49–60
  6. Chao KSC, Ozyigit G, Tran BN, et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2003;55:312–321
  7. Thomlinson R, Gray L. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9:539–549
  8. Hockel M, Knoop C, Schlenger K, et al. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv Exp Med Biol. 1994;345:445–450
  9. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509–4515
  10. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285–289
  11. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41:31–39
  12. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. [see comments] Nature. 1996;379:88–91
  13. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941–943
  14. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol. 2000;76:589–605
  15. De Jaeger K, Kavanagh MC, Hill RP. Relationship of hypoxia to metastatic ability in rodent tumours. Br J Cancer. 2001;84:1280–1285
  16. Brown JM. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine. Br J Cancer. 1998;77(Suppl. 4):12–14
  17. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005;23:79–87
  18. Kaanders JHAM, Pop LAM, Marres HAM, et al. ARCON: Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:769–778
  19. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551–560
  20. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171–1182
  21. Gronroos T, Eskola O, Lehtio K, et al. Pharmacokinetics of [18F]FETNIM: A potential marker for PET. J Nucl Med. 2001;42:1397–1404
  22. Dolbier WR, Li AR, Koch CJ, et al. [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl Radiat Isot. 2001;54:73–80
  23. Dehdashti F, Mintun M, Lewis J, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844–850
  24. Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study. Int J Radiat Oncol Biol Phys. 2008;70:2–13
  25. Nehmeh SA, Schoder H, Lee NY, et al. Reproducibility of the intra-tumoral distribution of 18F-flouromisonidazole (18F-MISO) in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235–242
  26. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417–428
  27. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435–5441
  28. Niemierko A. Reporting and analyzing dose distributions: A concept of equivalent uniform dose. Med Phys. 1997;24:103–110
  29. Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys. 2002;54:921–927
  30. Chaplin DJ, Olive PL, Durand RE. Intermittent blood flow in a murine tumor: Radiobiological effects. Cancer Res. 1987;47:597–601
  31. Dewhirst MW, Braun RD, Lanzen JL. Temporal changes in pO2 of R3230Ac tumors in fischer-344 rats. Int J Radiat Oncol Biol Phys. 1998;42:723–726

 Z.L. and J.M. contributed equally to this article.

 Supported in part by PO1 CA115675 from the National Cancer Institute/National Institutes of Health.

 Conflict of interest: none.

PII: S0360-3016(07)04368-4

doi: 10.1016/j.ijrobp.2007.09.050

International Journal of Radiation Oncology * Biology * Physics
Volume 70, Issue 4 , Pages 1219-1228 , 15 March 2008

Article Tools

* Image Usage & Resolution